University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund The University of Pennsylvania (“Penn”), BioNTech SE (“BioNTech”), and OUP (Osage University Partners) announced the launch of the $50 million Penn-BioNTech Innovative Therapeutics Seed Fund (“PxB Fund”), a dedicated venture…
Highlights recent progress across key R&D programs and outlines strategic priorities for 2026 Enanta Pharmaceuticals, Inc. a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs…
Phase 2 studies advance following encouraging clinical data for T-cell engagers in autoimmune diseases Candid Therapeutics, Inc. a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced continued clinical progress with…
WHO Global Summit Forges a Bold Vision for the Future of Traditional Medicine The second WHO Global Summit on Traditional Medicine, jointly organized with the Government of India, concluded today in New Delhi, marking a major milestone for global health as it drew…
Takeda’s Zasocitinib Demonstrates Landmark Phase 3 Results in Plaque Psoriasis, Offering Hope for Clear Skin with a Once-Daily Oral Therapy and Ushering in a New Treatment Era Takeda today announced positive topline results for the two pivotal Phase 3 randomized,…
Lilly’s Orforglipron Helps Sustain Weight Loss After Switching from Injectable to Oral GLP-1 Therapy in Pivotal Phase 3 Trial Eli Lilly and Company today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron, an investigational,…
CDC Officially Approves Delayed Hepatitis B Vaccine Dose The CDC has accepted the recommendation of its vaccine advisory committee and ended the three-decade-long practice of giving most newborn children a birth dose of the hepatitis B vaccine.The change in recommendation, announced Tuesday, leaves the…
Argenx Shares Update on UplighTED Clinical Trials of Subcutaneous Efgartigimod for Thyroid Eye Disease Argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies…
Merck Receives Positive CHMP Opinion in the EU for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH; WHO Group 1 Pulmonary Hypertension) Merck, known as MSD outside of the United States and Canada, today announced that…
Bio-Techne Collaborates with Wyss Center Geneva to Drive Innovation in Automated 3D Multiomics and Accelerate Spatial Biology Research Bio-Techne Corporation, a global provider of life science tools, reagents, and diagnostic products, today announced a strategic collaboration between one of its…
ICON plc, a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in…
Phase 3 MajesTEC-3 Study Delivers Unprecedented Results, Positioning TECVAYLI® Plus DARZALEX FASPRO® as a Potential New Standard of Care as Early as Second-Line Treatment for Relapsed/Refractory Multiple Myeloma Johnson & Johnson, the worldwide leader in multiple myeloma, today announced new…
